key: cord-0721147-ve8wgtvv
authors: Jemth, Ann-Sofie; Scaletti, Emma Rose; Homan, Evert; Stenmark, Pål; Helleday, Thomas; Michel, Maurice
title: NUDT18 catalyzes hydrolysis of active metabolites of the antivirals Remdesivir and Ribavirin
date: 2021-11-17
journal: bioRxiv
DOI: 10.1101/2021.11.16.468802
sha: 9ac1f3bb9499b05d1d40d74eb332a65c6ed1191e
doc_id: 721147
cord_uid: ve8wgtvv

Remdesivir (GS-5734) has gained considerable interest due to its activity against replication of SARS-CoV2. Remdesivir is a broad-spectrum antiviral prodrug that is hydrolyzed intracellularly and phosphorylated by cellular kinases to its active triphosphate form (Remdesivir-TP). Here we tested Remdesivir-TP as a substrate for a panel of human hydrolases and found that NUDIX hydrolase 18 (NUDT18) catalyzes the hydrolysis of Remdesivir-TP. NUDT18 is expressed in respiratory epithelial cells suggesting that NUDT18 may limit the antiviral efficacy of Remdesivir by decreasing the intracellular concentration of its active metabolite at its intended site of action. The kcat of NUDT18 for Remdesivir-TP was determined to 2.6 s-1 and the Km value was 156 μM, suggesting that NUDT18 catalyzed hydrolysis occurs in cells. In addition, we found that the triphosphate of the antiviral Ribavirin, with broad-spectrum activity against several RNA and DNA viruses, was hydrolyzed by NUDT18, albeit with a lower efficiency compared to Remdesivir-TP. NUDT18 activity was also tested with the triphosphates of the antivirals Sofosbuvir and Aciclovir for which low activity, in comparison to activities with Remdesivir-TP and Ribavirin-TP, was detected. These results suggest that NUDT18 can act as a cellular sanitizer and may influence the antiviral efficacy of Remdesivir and Ribavirin.

The recent SARS-CoV-2 pandemic with its fast worldwide spread and high mortality rate has led to major efforts to repurpose already approved antiviral drugs in order to quickly control the outbreak and thereby save lives. Remdesivir (GS-5734) was originally developed for the treatment of Ebola but is a broad-acting antiviral which reduces the replication of coronaviruses both in cell culture and animal models (1) . Remdesivir treatment was shown to decrease the severity of disease after MERS-CoV infection via decreasing virus replication and thereby reducing damage to the lungs when administered both before and after infection in a rhesus macaque model (1) . Recently, Remdesivir has been tested in several clinical trials for treatment of COVID-19 caused by the corona virus SARS-CoV2. Remdesivir was shown to shorten the recovery time in hospitalized adults with COVID-19 as well as reducing mortality rate (2) and suggested to be most effective if administered early after infection (3) . Remdesivir was approved for treatment of severe COVID-19 in July 2020 by the European Medicine Agency and later in the fall by the U.S Food and Drug Administration. (2, (4) (5) (6) . Remdesivir is a prodrug in form of a protected phosphate that upon cell entry ( Figure 1 , step 1) is metabolized by cellular enzymes to the corresponding phosphate (GS 441524, Figure 1 , step 2). Subsequently, the monophosphate is further phosphorylated by cellular kinases to its active triphosphate form (Remdesivir-TP, aka GS-443902, Figure 1 , step 3). The antiviral effect of Remdesivir-TP is mediated through its incorporation into the growing virus RNA chain by the viral RNA dependent RNA polymerase (RdRp, Figure 1 , step 4). The incorporated Remdesivir metabolite escapes the viral proofreading system and causes the polymerase to stall and RNA replication to be terminated ( Figure  1 , step 5) leading to a decrease in viral RNA (7, 8) . Ribavirin is another antiviral drug that was tested for activity towards SARS-COV2. Ribavirin has since the seventies been known as a broad-spectrum antiviral of both DNA and RNA viruses (9) . It has been used in combination with IFN-α-based therapy to treat hepatitis C (10) as well as other viral infections such as Lassa fever (11) , Crimean-Congo fever (12, 13) and chronic hepatitis E virus infections (14) . Ribavirin in combination with IFN-β was shown to synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines (15) suggesting that Ribavirin could be a potential treatment option for SARS-CoV2. The precise mode of action of Ribavirin is not completely understood and its metabolites have been suggested to target several processes of which the antiviral impact may depend on their intracellular concentrations (16) . Ribavirin-MP inhibits inosine monophosphate dehydrogenase leading to GTP depletion with effects on many cellular processes. Ribavirin-TP has been hypothesized to directly inhibit viral RNA dependent polymerase and may at higher concentrations also cause mutations in the viral genome. Ribavirin-TP is hydrolyzed by the ITPase hydrolase and patients carrying alleles encoding low activity ITPase variants display a reduced risk of hepatitis C relapse suggesting that these patients have higher concentrations of the active Ribavirin metabolite. Furthermore, low activity ITPase alleles have been shown to protect against anemia upon INFα and Ribavirin therapy (16, 17) . The ITPase activity dependent outcome of Ribavirin treatment strongly emphasizes the impact of cellular metabolism on drug efficiency. Similar to ITPase several NUDIX enzymes catalyze the hydrolysis of modified nucleoside triphosphates (18, 19) and have been shown to modulate the efficacy of various drugs including antivirals (20, 21) . An example is NUDT15 that we recently reported catalyzes the hydrolysis of Ganciclovir-TP. Similarly, hydrolysis of Remdesivir-TP into Remdesivir-MP catalyzed by a human nucleotide hydrolase (Figure 1 , Step 6) would reduce the cellular concentration of the active Remdesivir metabolite. Conversion of Remdesivir-MP to the corresponding nucleoside through the action of 5'nucleotidase would enable transport out from the cell (Figure 1, Step 7) and further decrease the antiviral potency of Remdesivir. In order to investigate if such a hydrolase could be found within the NUDIX family of enzymes we tested Remdesivir-TP as a substrate for a panel of human NUDIX hydrolases and found that NUDT18 catalyzed the hydrolysis of Remdesivir-TP. Encouraged by this we tested NUDT18 for activity with several antiviral triphosphates and found NUDT18 to also catalyze the hydrolysis of Ribavirin-TP. NUDT18 has to date only been described to display activity towards 8-oxo-GDP. It has therefore been suggested to cleanse the nucleotide pool from oxidatively damaged nucleotides, preventing their incorporation into DNA (22, 23) . The results of this study suggest that NUDT18 acts as a cellular sanitizer that contributes to removing modified nucleotides of both endogenous and exogenous origin, and potentially modulates the efficiency of the antiviral drugs Remdesivir and Ribavirin.

Protein production MTH1, NUDT15, NUDT18, NUDT5 and NUDT9, and E. coli PPase were produced as N-terminally His-tagged proteins and were expressed and purified by the Protein Science Facility, Karolinska Institute, using Ni-IMAC (HisTrap HP, GE Healthcare) followed by gel filtration (HiLoad 16/60 Superdex 75 or HiLoad 16/60 Superdex 100, GE Healthcare) as previously described (24) . Proteins were concentrated and then stored as aliquots at −80 °C in storage buffer (20 mM HEPES pH 7.5, 300 mM NaCl, 10% glycerol and 0.5 mM TCEP (tris-(carboxyethyl)phosphine)). ITPase, dUTPase and dCTPase were produced as N-terminally His-tagged proteins and expressed and purified as earlier described (25) .

Hydrolysis activity of MTH1, NUDT15, NUDT18, NUDT5 and NUDT9 (200 nM) with 100 µM Remdesivir-TP was assayed in reaction buffer (20 mM TrisAcetate pH 8.0, 40 mM NaCl, 10 mM MgAc, 1 mM DTT, 0.01% Tween20) by incubating reaction mix in wells of 96-well plates (NUNC) at 22°C for 30 minutes. Formed Pi was detected by addition of malachite green reagent (26) and measurement of absorbance at 630 nm. Activity of 200 nM MTH1, NUDT15, NUDT18 and NUDT5, with 100 µM Remdesivir-TP was also tested in the presence of E. coli PPase (0.2 U/ml) which converts formed PPi to Pi. Activity of the human pyrophoshates: ITPase, dUTPase and dCTPase with 100 µM Remdesivir-TP in the presence of PPase was assayed and compared to activity of NUDT18 with 100 µM 8-oxo-dGDP in the presence and absence of 0.2 U/ml PPase. Buffer controls with and without PPase were included and the background signal was subtracted from the assay data.

In order to test if NUDT18 can also hydrolyze Ribavirin-TP and to compare its activity towards Remdesivir-TP (BioCarbosynth) and 8-oxo-dGDP, 100 µM Ribavirin-TP (Jena Bioscience), Remdesivir-TP or 8-oxo-dGDP, respectively, was incubated with 10 nM NUDT18 in reaction buffer (20 mM TrisAcetate pH 8.0, 40 mM NaCl, 10 mM MgAc, 1 mM DTT, 0.01% Tween20) fortified with 0.2 U/ml PPase for 30 minutes at 22 °C after which formed Pi was detected by addition of malachite green reagent and measurement of absorbance at 630 nm in a Hidex spectrophotometer.

Initial rates of NUDT18 were determined in assay buffer (20 mM TrisAcetate pH 8.0, 40 mM NaCl, 10 mM MgAc, 1 mM DTT, 0.01% Tween20, 0.2 U/ml PPase) at concentrations ranging from 0 to 300 µM for Remdesivir-TP and from 0 to 200 µM for Ribavirin-TP, using 10 nM NUDT18. Reaction mixture was incubated for 0, 10 or 20 minutes. Formed Pi was detected by adding malachite green reagent and measurement of absorbance at 630 nm. A Pi standard curve was included on the plate and used to convert absorbance to concentration Pi. Enzyme saturation curves were also produced with 8-oxo-dGDP, which has been described to be the endogenous substrate of NUDT18, using the same enzyme concentration and buffer conditions. 8-oxo-dGDP concentrations ranging between 0 and 100 µM were used. Initial rates were calculated using linear regression and plotted against substrate concentration. The Michaelis-Menten equation was fitted to the data points and kinetic parameters of NUDT18 were determined using GraphPad Prism 8.0. Data points were measured in duplicate and two independent experiments were performed.

The finding that NUDT18 displays pronounced activity with the antiviral triphosphates Remdesivir-TP and Ribavirin-TP prompted us to also test the activity of NUDT18 with an expanded panel of antiviral triphosphates that are considered to be the active antiviral metabolite. The panel included the triphosphate of Sofosbuvir used for the treatment of hepatitis C (Sofosbuvir-TP, (2R)-(2'-deoxy-2'-fluoro-2-methyl-uridine-5'-TP, Sierra bioresearch), the triphosphate of Ganciclovir used to treat cytomegalovirus infection treatment (Ganciclovir-TP, Sierra bioresearch) and the triphosphate of Aciclovir used for Herpes simplex virus infection therapy, (Aciclovir-TP, Sierra bioresearch). We also included the active metabolite of the cytostatic drug gemcitabine (Gemcitabine-TP, Sierra bioresearch). NUDT18 (20 nM) was incubated with 100 µM of Ganciclovir-TP, Aciclovir-TP, Sofosbuvir-TP and Gemcitabine-TP for 30 min at 22 °C in assay buffer (20 mM TrisAcetate pH 8.0, 40 mM NaCl, 10 mM Magnesium Acetate, 1 mM DTT and 0.01% Tween 20), in absence and presence of PPase 0.2 U/ml. Formed Pi was detected by addition of malachite green reagent followed by measurement of absorbance at 630 nm.

Initial rates of NUDT18 (10 nM) were determined in assay buffer (20 mM TrisAcetate pH 8.0, 40 mM NaCl, 10 mM MgAc, 1 mM DTT, 0.01% Tween20, 0.2 U/ml PPase at concentrations ranging from 0 to 300 µM for Sofosbuvir-TP and Aciclovir-TP by incubating the reactions for 0, 10, 20 and 30 minutes. Formed Pi was detected by adding malachite green reagent and measurement of absorbance at 630 nm. The concentration of formed Pi was calculated using a Pi standard curve included on the assay plate. Enzyme saturation curves were also produced for dGTP using a concentration range between 0 and 200 µM. Initial rates were plotted against substrate concentration and the Michaelis-Menten equation was fitted to the data points allowing kinetic parameters of NUDT18 to be determined. Data points were measured in duplicate and two independent experiments were performed.

All calculations were performed using Schrödinger Suite 2021-1 [Schrödinger LLC, New York, NY, 2021]. Protein structure preparation. The apo structure of human NUDT18 (3GG6.pdb, unpublished) was prepared using the Protein Preparation Wizard. Briefly, the raw PDB structure was processed by automatically assigning bond orders, adding hydrogens, converting seleno-methionine to methionine, adding missing side chains, and creating possible disulfide bridges. Residues with alternate positions were locked in the conformations with the highest average occupancy. Hydrogen bonding networks were optimized automatically by optimization of hydroxyls, Asn, Gln, and His residue states using ProtAssign. A restrained minimization was then performed using the OPLS4 force field, until an RMSD convergence of 0.30 Å was reached for the heavy atoms. Binding site analysis. SiteMap was used to probe the prepared NUDT18 structure for possible ligand binding sites. The 5 top-ranked potential binding sites were identified. At least 15 site points per reported sites were required. The more restricted definition of hydrophobicity together with a standard grid (0.7 Å) were used. Site maps at 4 Å or more from the nearest site points were cropped. Ligand structure preparation. The structure of Remdesivir-TP was copied as isomeric smiles from PubChem (CID: 56832906) and pasted as 3D structure into Maestro. Ligprep was then used to prepare the structure of Remdesivir-TP for docking. The OPLS4 force field was used for minimizations; possible ionization states at pH 7.0 ± 2.0 were generated using Epik, and possible tautomers were generated; specified chiralities were retained and at most 1 stereoisomer was generated. Induced-fit docking. Remdesivir-TP was docked to NUDT18 using the Induced-Fit Docking protocol (27) . The site points of largest site identified by SiteMap were used to center the docking boxes. The size of the enclosing box was set to 20 Å. Glide XP was used for the redocking step, otherwise all settings were kept at default values.

Since Remdesivir-TP acts as a substrate of NUDT18 we decided to investigate if Remdesivir or its metabolites act as inhibitors of NUDT18 or its close relatives NUDT15 and MTH1. Activity of MTH1 (10 nM) and NUDT15 (10 nM) was tested in assay buffer (0.1 M TrisAcetate pH 7.5, 40 mM NaCl, 1 mM DTT, 10 mM MgAcetate) fortified with PPase (0.2 U/ml), with 100 µM dGTP in the presence of 1% DMSO or with 100 µM of Remdesivir-TP (#G167050, BioCarbosynth), Remdesivir (#AG170167, BioCarbosynth) or Remdesivir metabolite (#AG167808, BioCarbosynth). NUDT18 activity was assayed using 100 nM NUDT18 and 100 µM 8-oxo-dGDP in assay buffer. The reaction mixture was incubated for 30 min at 22°C after which formed Pi was detected by addition of malachite green reagent followed by absorbance measurements at 630 nm in a Hidex spectrophotometer.

NUDT18 catalyzes the hydrolysis of Remdesivir-TP and Ribavirin-TP In order to investigate if human NUDIX enzymes can modulate the cellular concentration of the active metabolite of Remdesivir and thereby reduce its efficacy as an antiviral drug we tested human MTH1, NUDT15, NUDT18, NUDT5 and NUDT9 for hydrolysis activity with Remdesivir-TP. Among the human NUDIX hydrolases tested only NUDT18 was found to catalyze the hydrolysis of Remdesivir-TP (Figure 2A) . NUDT18 was shown to catalyze the hydrolysis of the bond between the αand β-phosphate groups as well as the bond between the βand γ-phosphate groups (Figure 2A and B) as evidenced by an increase in the amount of Pi formed in the presence of PPase, which hydrolyzes PPi. Based on the described activity of ITPase with Ribavirin-TP, an active metabolite of the antiviral Ribavirin, we argued that ITPase may also hydrolyze other antiviral triphosphates. Thus, we tested human ITPase as well as the human hydrolases dCTPase and dUTPase for activity with Remdesivir-TP. Human dCTPase displayed low but measurable activity with Remdesivir-TP while no activity was detected with dUTPase or ITPase ( Figure 2C ). Comparison with NUDT18 activity towards 8-oxo-dGDP showed an approximately 2-fold higher specific activity compared to Remdesivir-TP at 100 µM substrate concentration ( Figure 2C ). The observed activity of NUDT18 with Remdesivir-TP prompted us to also test Ribavirin-TP as a substrate for NUDT18. We found that Ribavirin-TP is also hydrolyzed by NUDT18, albeit not to the same extent as Remdesvir-TP (Figure 3 ). Similar to Remdesivir-TP, Ribavirin-TP is hydrolysed to both the corresponding di-and monophosphate, as shown by an increase in the signal when PPase was included in the assay buffer ( Figure 3 ). In comparison with 8-oxo-dGDP the specific activity of NUDT18 is lower for both Remdesvir-TP and Ribavirin-TP. To investigate the activity of NUDT18 with Remdesivir-TP and Ribavirin-TP in more detail we performed kinetic analyses of the NUDT18-catalyzed reactions using Remdesivir-TP, Ribavirin-TP and 8-oxo-dGDP by producing enzyme saturation curves ( Figure 4A , B and C). We determined kinetic parameters for these substrates under identical conditions ( Figure 4F ). The Km value for NUDT18 was determined to be 16.5 µM for 8-oxo-dGDP, which is comparable with a previously published Km-value of 12 µM (22) . The kcat value for 8-oxo-dGDP at 22°C was determined to be 1.8 s -1 and the calculated kcat/Km value was 109,800 M -1 s -1 . The Km value for Remdesivir-TP was determined to be 156 µM (n=2) and the kcat value was 2.6 s -1 resulting in a kcat/Km value of 17,700 M -1 s -1 . The approximately 6-fold higher specificity constant (kcat/Km value) of NUDT18 for 8-oxo-dGDP implies that 8-oxo-dGDP would be the preferred substrate over Remdesivir-TP at the same concentration. However, the concentration of Remdesivir in monkey lung cell tissue post IV administration is estimated to be 800 nM (28) . Based on an estimation of the intracellular 8-oxo-dGTP concentration of 2 nM in U2OS cells (29) , and the assumption that the cellular concentration of 8-oxo-dGDP likely is in a similar range or lower, one can conclude that the cellular Remdesivir-TP concentration is likely to be at least 100-fold higher than the concentration of 8-oxo-dGDP in vivo. This suggests that the activity of NUDT18 with Remdesivir-TP may be of relevance for modulating the Remdesivir-TP concentration in cells.

When comparing Remdesivir-TP and Ribavirin-TP as substrates for NUDT18, Remdesivir-TP appears to be the preferred substrate. NUDT18 displays a kcat value for Ribavirin-TP hydrolysis that is approximately 1 s -1 and a Km-value of 111 µM, resulting in a catalytic efficiency value of 8,800 s -1 M -1 , which is approximately half of the corresponding value for Remdesivir-TP ( Figure 4F ). Comparison of the kinetic parameters of Remdesivir-TP and Ribavirin-TP with those for 8-oxo-dGDP show that the difference primarily lies in the Km value suggesting a better fit of 8-oxoguanine in the active site of NUDT18.

In order to investigate if NUDT18 can catalyze the hydrolysis of other antiviral triphosphates we expanded the substrate screen of NUDT18 to include several antiviral triphosphates. We found that Sofosbuvir-TP, Aciclovir-TP, Ganciclovir-TP as well as Gemcitabin are also hydrolyzed by NUDT18 to some extent. Similar to the NUDT18-catalyzed hydrolysis of Remdesivir-TP and Ribavirin-TP, hydrolysis takes place at both the β-γ and the α-β phosphate bonds in these substrates with approximately 50% of the hydrolysis taking place at each of these positions ( Figure 4D ). Kinetic analysis revealed that the activity with Aciclovir-TP, the best substrate in this panel of substrates, is much lower compared to the activity with Remdesivir-TP with a kcat/Km value approximately 5 times lower ( Figure 4E and F) . However, the kcat/Km value was still 2.2 times higher than the corresponding kcat/Km value for dGTP. The fact that Aciclovir contains a guanine moiety like dGTP indicates that the higher activity of NUDT18 with Aciclovir-TP compared to dGTP lies in NUDT18 being able to better accommodate the nucleobase and the modified sugar part of Aciclovir-TP in the active site. This enables a positioning of the phosphate groups which is more productive for hydrolysis. This is reflected by a 2.6 times higher turnover number (kcat) for Aciclovir-TP compared to dGTP, while the Km values are comparable ( Figure 4F ). Whether the activity of NUDT18 with these antiviral triphosphates bears clinical relevance for modulating the potency of these antivirals needs further investigation.

Remdesivir-TP contains a nitrile group on the C1 atom of the ribose unit ( Figure 5 ). The fact that none of the other tested NUDIX proteins displays any activity with Remdesivir-TP suggests that only the active site of NUDT18 is spacious enough and contains amino acids enabling accommodation of this moiety while still orienting the rest of the molecule allowing for efficient hydrolysis. To date two crystal structures of human NUDT18 have been disclosed (PDB IDs: 3gg6 and 4hvy), both comprising apo structures of truncated constructs covering residue positions 26-179. Analysis using SiteMap [SiteMap, Schrödinger, LLC, New York, NY, 2021] indicated that the largest pocket adjacent to the helix containing the NUDIX motif is relatively small and polar in comparison to other NUDIX family members (30) . Docking of Remdesivir-TP to this site did not yield any good-scoring poses with plausible accommodation of the heterocyclic core of Remdesivir-TP. In comparison, the homologous NUDIX family members NUDT1 and NUDT15 contain deeper druggable pockets which readily accommodate nucleobases and small-molecule inhibitors (25, 31) . This suggests that considerable conformational changes are required for NUDT18 to harbour the heterocyclic cores of Remdesivir-TP and other substrates. Attempts to induce a deeper hydrophobic pocket using an induced-fit procedure as described by Loving et al. (32) also failed to generate a pocket for Remdesivir-TP with significantly improved SiteScore. In order to obtain structural information to understand the binding mode of NUDT18 substrates we carried out extensive crystallization trials of full length NUDT18 without added ligands or together with 8oxo-dGDP, Remdesivir-TP or Ribavirin-TP. This included seven different commercially available crystallization screens (JCSG+, INDEX, Morpheus, Morpheus II, Pact Premier, Structure Screen and Salt-RX) using different protein concentrations (ranging from 5 mg/mL to 25 mg/mL) and temperatures (4 °C and 20 °C). Unfortunately, we were not able to obtain crystals in any of the conditions tested. As only structures of the nucleosidase binding domain are available for NUDT18 it is possible that the second domain and linking region renders the full-length protein too flexible for crystallization. We performed a structural similarity search using the DALI web server (33) , which indicated that hNUDT18 is most structurally similar to human and other eukaryotic MTH1 proteins from dogs, mice and zebrafish (with rms differences of 2.1 to 2.3 Å). As Remdesivir-TP is an analogue of ATP we were particularly interested in comparing the existing hNUDT18 nucleotidase domain structure (PDB ID: 3gg6) with structures of hMTH1 bound to N6-methyl-dAMP (PDB ID: 6qvo, (19) and 2OH-dATP (PDB ID: 5ghq, (34) . Comparison of these structures showed that residues from the highly conserved NUDIX motif (GX5EX7REVXEEXGU) that coordinate the essential magnesium ions required for substrate hydrolysis superimpose nicely between the structures (Supplementary Figure 1A) . This provides some level of certainty as to where the αphosphate group of Remdesivir-TP would be positioned in hNUDT18 and therefore the orientation of the ligand within the binding pocket. Analysis of the hNUDT18 reveals a shallow binding pocket (Supplementary Figure 1B) and structural rearrangements are clearly required to accommodate the adenine base. Analysis of N6-methyl-dAMP and 2OH-dATP binding in MTH1 shows that the residue W117* forms an important pi-stacking interaction with the adenine base. In NUDT18 the corresponding residue is an alanine, however a tyrosine residue (Y72, N33* in hMTH1) which would be capable of performing an equivalent pi-stacking interaction is situated in close proximity (Supplementary Figure 1C) . In the current NUDT18 apo structure Y72 clashes with the bound base when compared to the ligands in the hMTH1 structures. A conformational adjustment must occur in order to make room for the substrate. Repositioning of this tyrosine would shape the binding pocket in such a way that it, while still being shallow, is capable of accommodating N6-methyl-dAMP and 2OH-dATP and importantly, Remdesivir-TP with its additional nitrile group (Supplementary Figure 1D) . The lower K m value of 8-oxo-dGDP for NUDT18 suggests it fits better within the active site of the enzyme than Remdesivir-TP. In the absence of a fulllength NUDT18 structure, a structure of the NUDT18 nucleotidase domain bound to the natural substrate 8-oxo-dGDP or to Remdesivir-TP would be very useful for elucidating the exact structural rearrangements that occur within the nucleotide binding site upon binding of these ligands.

In an attempt to understand what structural features of the substrates determine their quality as NUDT18 substrate, we calculated the values of catalytic efficiency and turnover number of NUDT18 for the tested substrates relative to the corresponding values for dGTP. In addition, we examined the chemical structures of the tested substrates ( Figure 5 ). NUDT18 has previously been reported to catalyze the hydrolysis of 8-oxo-dGDP and 8-oxo-GDP with the same efficiency (22) , demonstrating that the 2'-OH group can be accommodated in the active site of NUDT18. This suggests a flexibility towards alterations within this part of the nucleoside substrate. Among the tested substrates, the turnover number is highest for Remdesivir-TP suggesting that either NUDT18 catalyzed hydrolysis or product release is faster for Remdesivir-TP compared to 8-oxo-dGDP under substrate saturating conditions. However, the Km-value is considerably lower for 8-oxo-dGDP ( Figure 4F ), indicating specific interactions between the oxidized nucleobase and the active site of NUDT18. The lower Km value, which translates into higher catalytic efficiency for 8-oxo-dGDP, may in part be due to nucleoside triphosphates binding with lower affinity to the active site compared to nucleoside diphosphates. The difference in catalytic efficiency between Remdesivir-TP and Ribavirin-TP can likely be attributed to differences in positioning for efficient hydrolysis and/or product release since their Km values are similar. Interactions between the nucleobase and/or the nitrile group of Remdesivir-TP and NUDT18 may contribute to a more productive binding. However, in absence of structural information, it is difficult to draw any conclusions about the binding mode. Nevertheless, the fact that the active site of NUDT18 can accommodate molecules with rather different structures and that hydrolysis takes place at two positions with equal efficiency indicates a relatively flexible binding mode for these substrates.

Since Remdesivir-TP was found to be a substrate for NUDT18 we argued that Remdesivir and its metabolites may inhibit NUDT18 and related NUDIX proteins. We therefore tested MTH1 and NUDT15 for inhibition by Remdesivir, the Remdesivir metabolite GS 441524 (arising from cellular hydrolysis of Remdesivir) and Remdesivir-TP, and NUDT18 for inhibition by Remdesivir and GS 441524. NUDT15 was found to be modestly inhibited by 100 µM Remdesivir (26 %) as well as by GS 441524 (21 %) ( Figure 6 ). MTH1 was slightly inhibited by GS 441524 (23%) while no inhibition of NUDT18 by any of the tested Remdesivir compounds was observed. The modest inhibitory effect of Remdesivir and its metabolites imply that Remdesivir treatment is unlikely to have a pronounced effect on the cellular activity of these enzymes.

The results presented here suggest that NUDT18 can convert Remdesivir-TP to Remdesivir-DP and Remdesivir-MP in the cell. However, since Remdesivir-DP and Remdesivir-MP are substrates for adenylate kinase 2 they will be phosphorylated and a cellular equilibrium between production of Remdesivir-TP by kinases and hydrolysis catalyzed by NUDT18 is likely established. Furthermore, the action of intracellular 5'-nucleotidase may affect the concentration of Remdesivir-MP. For NUDT18 to play a clinically relevant role in modulating Remdesivir efficacy it has to be present in the cells that are infected by the virus. NUDT18 is ubiquitously expressed, displays low tissue specificity (https://www.proteinatlas.org/ENSG00000275074-NUDT18) and importantly is found in lung (https://www.ebi.ac.uk/gxa/home) and in respiratory epithelial cells. This suggests that NUDT18 would be able to modulate the effective concentration of Remdesivir-TP at its intended site of action. Potentially, inhibition of NUDT18 would be a means to increase the efficacy of Remdesivir. However, no NUDT18 inhibitors are available to the best of our knowledge. The importance of intracellular metabolism for efficiency of antivirals is exemplified by the activity of human ITPase with Ribavirin-TP (16) . Approximately a third of the human population carries low activity ITPase alleles (16) and it is clear that cellular ITPase activity influences the antiviral efficacy of Ribavirin as well as its adverse effects. Similarly, higher expression of NUDT18 in respiratory epithelial cells in a COVID-19 patient, potentially resulting in considerable Remdesivir-TP hydrolysis, may result in lower efficiency of Remdesivir compared to in a patient with lower NUDT18 expression levels. This may explain observed differences in response to Remdesivir treatment between patients. Here we show that human NUDT18 can catalyze the hydrolysis of the active metabolites of the antivirals Remdesivir and Ribavirin. This novel NUDT18 activity may be clinically relevant and warrants further investigation and emphasizes the need for NUDT18-specific inhibitory chemical probes to be able to investigate the cellular NUDT18 function and role in modulating efficacy of these antiviral drugs. In summary, we suggest a potential cellular role of NUDT18 as a sanitizer of modified nucleotides, including antiviral triphosphates in the cell. , NUDT5, was also tested in presence of PPase (0.2 U/ml) that converts formed PPi to Pi. (C) Activity of the human pyrophoshatases ITPase, dUTPase and dCTPase with 100 µM Remdesivir-TP was assayed in presence of PPase was assayed and compared to activity of NUDT18 with and without PPase and to NUDT18 activity with 100 µM 8-oxo-dGDP. (D) Hydrolysis products of NUDT18 catalyzed hydrolysis of Remdesivir-TP in presence and absence of NUDT18. . Inhibition of NUDIX enzymes by Remdesivir and its metabolites. MTH1 and NUDT15 was tested for inhibition by 100 µM Remdesivir-TP, Remdesivir or Remdesivir metabolite (GS441524) in an activity assay using 100 µM dGTP as substrate and 10 nM NUDT15 or MTH1. The potency of Remdesivir and Remdesivir metabolite (GS441524) to inhibit NUDT18 was tested in an assay using 100 µM 8-oxo-dGDP as substrate and using 100 nM NUDT18. NUDT15 is modestly inhibited by Remdesivir and activity of all three enzymes are reduced by approximately 20% in presence of the Remdesivir metabolite (GS441524).

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Remdesivir for the Treatment of Covid-19 -Final Report

The time to offer treatments for COVID-19

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Directly Acting Antivirals for COVID-19: Where Do We Stand? Front Microbiol

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. Mbio

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

Intervention strategies for emerging viruses: use of antivirals

Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis

Severity Scoring Index for Crimean-Congo Hemorrhagic Fever and the Impact of Ribavirin and Corticosteroids on Fatality

Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients

Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines

Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP

MutT homologue 1 (MTH1) removes N6-methyl-dATP from the dNTP pool

NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine

NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir

Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2

The roles of human MTH1, MTH2 and MTH3 proteins in maintaining genome stability under oxidative stress

A comprehensive structural, biochemical and biological profiling of the human NUDIX hydrolase family

MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool

A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay

Novel procedure for modeling ligand/receptor induced fit effects

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit

Direct Measurement of the Intracellular Concentration of 8-Oxo-2'-Deoxyguanosine-5'-Triphosphate by LC-MS/MS

silicoDruggability Assessment of the NUDIX Hydrolase Protein Family as a Workflow for Target Prioritization. Front Chem

Development of a chemical probe against NUDT15

Structure-Based Druggability Assessment of the Mammalian Structural Proteome with Inclusion of

Dali server: conservation mapping in 3D

Structural and Kinetic Studies of the Human Nudix Hydrolase MTH1 Reveal the Mechanism for Its Broad Substrate Specificity

All data are available from the authors upon request. 

The authors thank the Protein Science Facility at Karolinska Institutet/SciLifeLab (http://ki.se/psf) for protein production and Mari Kullman Magnusson for excellent laboratory support and Louise Sjöholm for administrative support. We thank Dr Maeve Long for linguistic corrections. We thank the Swedish Research Council, the Swedish Cancer Society, the Knut and Alice Wallenberg Foundation, the Torsten and Ragnar Söderberg Foundation, the Alfred Österlund foundation, Åke Olsson foundation, EUbOPEN and KI funds for financial support.